ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO109

Novel Exosome-Based Therapeutics Targeting NF-kB/p65 for AKI

Session Information

  • AKI: Mechanisms - III
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Choi, Chulhee, ILIAS Biologics Inc., Daejeon, Korea (the Republic of)

Either systemic or local inflammation-induced by infection or ischemic reperfusion is the key pathophysiological event driving sepsis associated (SA)- and cardiac surgery-associated (CSA)-AKI development. NF-kB signaling pathway plays a pivotal role in driving inflammation in both SA- and CSA-AKI. Effective/specific inhibition of NF-kB signaling pathway may ameliorate the course of SA- and CSA-AKI. Recent advancements in nano-technology made it feasible to specifically target NF-kB signaling. The intracellular delivery of protein API (NF-kB inhibitor) with exosome as DDS is an attractive approach for tackling NF-kB signaling in the target cells without off-target effect in both SA- and CSA-AKI.




Utilizing ILIAS Bio’s EXPLOR® (EXosome engineering for Protein Loading via Optically Reversible protein-protein interactions) technology, we have developed Exo-srIκB with srIκB as API which is a constitutively active form of IκBα with a prolonged half-life in the target cells. Exo-srIκB exhibits anti-inflammation function via specific inhibition of stimuli-induced NF-kB/p65 activation. In the septic mice, the treatment of Exo-srIκB inhibits systemic inflammation and improves survival with the amelioration of SA-AKI. In the renal ischemic-reperfusion mice, the treatment of Exo-srIκB alleviates IRI-AKI by down-regulating NF-kB signaling and ameliorating inflammation/apoptosis in the ischemic injured kidney.


The direct intracellular delivery of immunosuppressive protein (srIκB) into target cells using exosomes can be used as a promising therapeutic approach for both SA- and CSA-AKI. The therapeutic potential of Exo-srIκB in both SA- and CSA-AKI should be explored further by clinical trials. Via GLP-toxicology and safety pharmacology studies, it has been determined that Exo-srIκB has no toxicity with minimum 20 folds safety margin compared to the efficacy dose, and based on repeated dose study, both NOAEL and HED were determined, which grant Exo-srIκB first-in-human (FIH) study.